A modified microchip-based flow chamber system for evaluating thrombogenicity in patients with thrombocytopenia

Bengo Atari 1, Takashi Ito 2*, Tomoka Nagasato 3, Tomoko Ohnishi 3, Kazuya Hosokawa 3, Tomotsugu Yasuda 1, Ikuro Maruyama 2 and Yasuyuki Kakihana 1

Abstract

Background: In the intensive care unit (ICU), patients with thrombocytopenia are at high risk for bleeding and should be assessed for their thrombogenic potential. However, the analytical conditions of conventional hemostatic tests are unsuitable for the evaluation of low-platelet samples. Here we aimed to establish suitable analytical conditions with the Total Thrombus-formation Analysis System (T-TAS) for quantitative assessment of thrombogenic potential in patients with thrombocytopenia and to investigate how T-TAS values relate to bleeding symptoms and the effects of platelet transfusion.

Methods: Modified chips with a different chamber depth were developed for the analysis of low-platelet samples in the T-TAS. We included 10 adult patients admitted to the ICU of Kagoshima University Hospital who required platelet transfusion. Patients were divided into major and minor bleeding groups according to their bleeding scale before platelet transfusion. The thrombogenic potential of these patients before and after platelet transfusion was assessed with hemostatic function tests, including rotational thromboelastometry, multiplate aggregometry, and the T-TAS.

Results: Analysis of low-platelet samples revealed that, compared with the conventional chip (80-μm-deep chamber), the modified chip (50-μm-deep chamber) achieved higher sensitivity in detecting elevation of flow pressure caused by growth of an occlusive thrombus in the T-TAS analytical chamber. All patients in the minor bleeding group retained thrombogenic potential that occluded the modified chip (occlusion time 16.3 ± 3.3 min), whereas most patients in the major bleeding group were unable to occlude the modified chip during the 30-min measurement (P < 0.01). The recovery of thrombogenic potential after platelet transfusion was confirmed with the T-TAS and correlated with the function, rather than the count, of transfused platelets. Among all evaluated parameters in hemostatic function tests, only the T-TAS showed significant differences in occlusion time and area under the curve both between the minor and major bleeding groups and between pre- and post-platelet transfusion.

Conclusions: We developed a modified microchip-based flow chamber system that reflects the hemostatic function of patients with thrombocytopenia.

Keywords: Thrombocytopenia, Platelet transfusion, Bleeding, Flow chamber, Total Thrombus-formation analysis system (T-TAS)

* Correspondence: takashi@m3.kufm.kagoshima-u.ac.jp
2Department of Systems Biology in Thromboregulation, Kagoshima
University Graduate School of Medical and Dental Sciences, 8-35-1
Sakuragaoka, Kagoshima 890-8544, Japan
Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Patients in the intensive care unit (ICU) often experience thrombocytopenia. Causes of thrombocytopenia include loss of platelets resulting from hemorrhage, dilution resulting from fluid resuscitation, consumption resulting from platelet adhesion to the vascular wall or extracorporeal devices, and insufficient production resulting from hematopoietic disease or adverse drug effects [1–3]. To manage thrombocytopenia, it is important to identify and eliminate its causes and, if necessary, transfuse platelets to stabilize hemostasis and hemodynamics.

Practice criteria for platelet transfusion are controversial. Platelets may be transfused to patients with thrombocytopenia during treatment of hematopoietic disease, before insertion of a central venous catheter, before diagnostic lumbar puncture, and before surgery. Practice criteria are not standardized and depend to a large extent on the circumstances mentioned above [4–8]. Randomized controlled trials comparing patients with hematopoietic disease who received prophylactic platelet transfusion when platelets fell to <10,000/μL with those who received platelet transfusion after bleeding symptoms appeared found that the former group underwent transfusions more frequently. However, these patients experienced fewer bleeding events, suggesting the benefit of prophylactic platelet transfusion [9–11]. The frequency of bleeding events in patients with hematopoietic malignancies does not significantly differ when the trigger value for platelet transfusion is 10,000/μL versus 20,000/μL [12–14]; therefore, a platelet count of 10,000/μL has been proposed as the transfusion trigger value. However, platelet counts do not significantly correlate with bleeding events [15], suggesting that indicators more closely related to bleeding symptoms may be more appropriate for assessing the need for platelet transfusion.

Thromboelastometry and multiplate impedance aggregometry are widely used for analyzing hemostatic function. Thromboelastometry, which monitors changes in the viscoelasticity of whole blood during formation of the fibrin clot, is mainly used to evaluate hemostatic function during cardiovascular surgery [16–18]. Multiplate impedance aggregometry, which monitors the increase in electrical resistance between electrodes caused by platelet aggregation, is used to evaluate the efficacy of antithrombotic drugs [19–21]. These methods are employed worldwide as point-of-care hemostatic function tests using whole blood. However, the ability of these tests to evaluate hemostatic function in patients with thrombocytopenia and to determine the requirements for platelet transfusion have not been established.

We developed the Total Thrombus-formation Analysis System (T-TAS), which comprehensively evaluates hemostatic function under conditions similar to those of thrombus formation in vivo [22]. The T-TAS monitors the elevation in flow pressure, which reflects the growth of a platelet- and fibrin-rich thrombus in the flow chamber, which is embedded in an analytical chip. Recent studies have suggested that T-TAS values are a significant predictor of bleeding events [23, 24]. However, as with other conventional hemostatic function tests, the analytical conditions of the T-TAS are not suitable for evaluating hemostatic function in patients with thrombocytopenia. Here we developed analytical conditions suitable for the evaluation of hemostatic function of low-platelet samples by adjusting the depth of the T-TAS flow chamber. We further determined how the values acquired with the modified T-TAS were related to bleeding symptoms as well as the effects of platelet transfusion in patients with thrombocytopenia.

Methods
Blood sampling
This single-center observational study was approved by the Ethics Committee of Kagoshima University Hospital (approval no. 170178–2). The study was conducted in compliance with the Declaration of Helsinki, and written informed consent to participate was obtained from patients or their close relatives. We included 10 adult patients admitted to the ICU of Kagoshima University Hospital between November 2017 and October 2019 who required a platelet transfusion. We excluded patients administered drugs that affect the hemostatic system, such as antiplatelet agents or anticoagulants. The use of anticoagulants for the maintenance of arterial lines or extracorporeal devices was permitted. The need for platelet transfusion was determined in accordance with our standard clinical practice, independent of the present study.

Blood was drawn from the radial arterial line before and after platelet transfusion. The samples were anticoagulated with EDTA (Becton Dickinson Co., Fukushima, Japan), 3.2% sodium citrate (Terumo, Tokyo, Japan), or hirudin (Roche Diagnostics GmbH, Mannheim, Germany) and were used for blood cell counts, thromboelastometry, T-TAS, and multiplate aggregometry. After platelet transfusion, platelet concentrates remaining in the transfusion tube were collected and analyzed for their thrombogenic potential.

Assessment of bleeding scale
Before platelet transfusion, bleeding symptoms were assessed with the modified WHO bleeding scale [4]. Grades 0, 1, 2, 3, and 4 corresponded to minimum, minor, moderate, severe, and debilitating bleeding, respectively. Patients were divided into two groups according to their bleeding scale before platelet transfusion: the minor bleeding group, which included patients with a
bleeding grade ≤ 1, and the major bleeding group, which included patients with a grade ≥ 2.

**Laboratory tests**
Platelet counts were measured with an XN-9000 automated blood cell analyzer (Sysmex, Kobe, Japan). General coagulation tests, including measurement of prothrombin time (PT), activated partial thromboplastin time (APTT), and fibrinogen, were performed with the Automated Coagulation System-CP3000 (Sekisui Medical, Tokyo, Japan) or a STACIA (LSI Medience, Tokyo, Japan).

**Rotational thromboelastometry (ROTEM)**
Blood anticoagulated with sodium citrate was used for ROTEM (Instrumentation Laboratory). Tissue factor-induced blood coagulation (EXTEM) and ellagic acid-induced blood coagulation (INTEM) were analyzed with ROTEM according to the protocol recommended by the manufacturer, and clotting time and maximum clot firmness were evaluated.

**Multiple electrode aggregometry**
Blood anticoagulated with hirudin was used for multiple electrode aggregometry with a Multiplate Analyzer (Roche). Platelet aggregation induced by collagen, adenosine diphosphate (ADP), thrombin receptor activating peptide-6 (TRAP-6), or ristocetin was analyzed according to the protocol recommended by the manufacturer, and the area under the curve (AUC) was evaluated.

**T-TAS analysis**
Blood anticoagulated with sodium citrate was used for T-TAS analysis (Fujimori Kogyo, Tokyo, Japan). Calcium chloride and corn trypsin inhibitor were added at the start of the measurement. In some experiments, platelet concentrates (240 μL) mixed with pooled normal plasma (240 μL) (George King Bio-Medical, Inc., Overland Park, KS, USA) and a reagent mix (20 μL) containing calcium chloride, corn trypsin inhibitor, aprotinin, and heparan sulfate were used for T-TAS analysis to evaluate the hemostatic function of platelet concentrates. Thrombus formation in the flow chamber, which was coated with tissue factor and collagen, was analyzed according to the protocol recommended by the manufacturer, and occlusion time and the AUC were evaluated. For the analysis of low-platelet samples, newly developed flow chambers (width, 300 μm; depth, 60 μm or 50 μm) were used instead of conventional flow chambers (width, 300 μm; depth, 80 μm). The flow rate was set at 10 μL/min, which corresponds to initial wall shear rates of approximately 1500, 1100, and 600 s⁻¹ in the 50-, 60-, and 80-μm-deep chambers, respectively. The intra-assay coefficient of variation of the AUC was 1.24% when using conventional flow chambers and whole blood from healthy volunteers [25].

**Immunofluorescence analysis of flow chambers**
Immediately after the T-TAS analysis, immunofluorescence analysis was performed to determine the composition of thrombi formed in the flow chamber [22]. Platelets in unfixed thrombi were labeled with FITC-conjugated mouse anti-human CD41 IgG (Beckman Coulter, Miami, FL, USA) for 15 min in the dark. After fixation with OptiLyse C (Beckman Coulter), fibrin (ogen) was detected by using rabbit anti-human fibrinogen IgG (Dako, Tokyo, Japan) labeled with Alexa Fluor 594 (Invitrogen, Carlsbad, CA, USA) for 30 min in the dark. The nuclei of leukocytes were stained with 4’,6-diamidino-2-phenylindole dihydrochloride (Dojindo, Kumamoto, Japan). The entire image of thrombi formed in the flow chamber was analyzed with a BX-X700 All-in-One Fluorescence Microscope (Keyence Corp., Osaka, Japan). Although fibrin generation could continue until fixation with OptiLyse C, this had little impact on the results.

**Statistical analysis**
The significance of differences between the major and minor bleeding groups was evaluated with the Student t test. The significance of differences before versus after platelet transfusion was evaluated with the paired t test. Relationships between hemostatic function test values were evaluated with Pearson’s correlation coefficients and P values. All statistical analyses were performed with IBM SPSS version 23 (Armonk, NY, USA), and a P value < 0.05 was considered to indicate a significant difference.

**Results**
**Novel flow chambers for evaluating thrombogenicity of low-platelet samples**
When we used conventional T-TAS chips with a chamber depth of 80 μm to analyze low-platelet samples, the flow pressure did not increase during the 30-min measurement (Fig. 1a). This finding indicates that conventional T-TAS chips are unsuitable for quantitative analysis of hemostatic function in patients who require a platelet transfusion. To detect an elevation in flow pressure in low-platelet samples, we developed modified chips with a chamber depth of 60 μm or 50 μm. When we used the 50-μm chip, the flow pressure increased after platelet transfusion (Fig. 1a). Immunofluorescence analysis revealed that platelet transfusion resulted in enlargement of platelet-rich thrombi covered with a fibrin (ogen) mesh that filled the chamber (Fig. 1b). Large numbers of leukocytes were trapped in the platelet-rich thrombi after platelet transfusion. We subsequently used the 50-μm chips, designated HD chips, instead of the conventional AR chips for the analysis of low-platelet samples in the T-TAS.
We next analyzed the relationship between bleeding symptoms and the values of hemostatic function tests, including ROTEM, the Multiplate Analyzer, and the T-TAS, in 10 patients requiring platelet transfusion (Table 1). Of these, six patients were categorized into the major bleeding group and four were categorized into the minor bleeding group. Most conventional test values other than the EXTEM clotting time did not significantly differ between the major and minor bleeding groups (Table 2). In contrast, the occlusion time and the AUC of the T-TAS HD chips did significantly differ between groups ($P < 0.01$). When the T-TAS HD chip was used, all four patients in the minor bleeding group retained thrombogenic potential to occlude the flow chamber. In contrast, patients in the major bleeding group showed delayed or defective thrombus formation in the T-TAS HD chips (Fig. 2). These findings suggest that T-TAS values were closely related to bleeding tendency and may therefore be useful for quantitative analysis of hemostatic function of patients with thrombocytopenia.

Differences in values of hemostatic function tests before versus after platelet transfusion

We next analyzed differences in the values of hemostatic function tests before versus after platelet transfusion. When we measured thrombogenicity with the Multiplate Analyzer, there was no significant difference before versus after platelet transfusion. In contrast, the maximum clot firmness determined with the ROTEM and the thrombogenic potential determined with the T-TAS were significantly higher after platelet transfusion than before transfusion (Fig. 3). Patients with low T-TAS values even after platelet transfusion required repeated platelet transfusions (Table 3).

Because the recovery rate of thrombogenic potential after platelet transfusion ($\Delta$AUC of T-TAS) varied from one case to another, we examined factors closely related to this rate. The $\Delta$AUC of the T-TAS in patients significantly correlated with the AUC of the T-TAS of the platelet concentrate, but did not correlate with the number of platelets in the platelet concentrate (Fig. 4, upper panel). The AUC of the T-TAS of platelet concentrates did not correlate with the number of platelets or the storage period of platelet concentrates (Fig. 4, lower panel).
These findings indicate that the recovery rate of thrombogenic potential after platelet transfusion may depend on the function, rather than the count, of platelets in the platelet concentrate.

Discussion

The major findings of this study are as follows. (1) We developed modified T-TAS HD chips suitable for quantitatively evaluating hemostatic function in patients with thrombocytopenia. (2) T-TAS HD chips discriminated between hemostatic function of the major and minor bleeding groups. (3) T-TAS HD chips detected the recovery of hemostatic function following platelet transfusion. (4) The recovery of hemostatic function following platelet transfusion may depend on the function of transfused platelets, rather than the count. The advantages of T-TAS HD chips do not necessarily suggest that the T-TAS is superior to conventional hemostatic function tests, such as those obtained with the Multiplate Analyzer and ROTEM, because suitable analytical conditions for low-platelet samples are indispensable, not only for the T-TAS but also for the Multiplate Analyzer and ROTEM.

It is important to determine whether evaluation of hemostatic function with the T-TAS supports clinical decision-making. For example, the ability of the T-TAS to indicate the need for platelet transfusion should be clarified in the future. Answering this critically important

Table 1  Patients’ baseline characteristics

| Patient | Age | Sex | Underlying disease       | Platelet count (10³/µL) | Bleeding scale | Sites and duration | Reason for transfusion |
|---------|-----|-----|---------------------------|-------------------------|----------------|--------------------|------------------------|
| 1       | 84  | F   | Microscopic polyangitis   | 25                      | 1              | Soft tissue, temporal | Prophylactic          |
| 2       | 36  | M   | SLE                       | 58                      | 3              | Oral cavity, persistent | Bleeding tendency     |
| 3       | 52  | F   | TAFRO syndrome            | 43                      | 0              | None                | Before the invasive procedure |
| 4       | 70  | F   | Acute liver failure       | 27                      | 2              | Soft tissue, temporal | Bleeding tendency     |
| 5       | 65  | M   | Alcoholic liver hepatitis | 11                      | 4              | GI tract, persistent | Bleeding tendency     |
| 6       | 44  | F   | Acute pancreatitis        | 53                      | 1              | Soft tissue, temporal | Prophylactic          |
| 7       | 76  | M   | Sepsis                    | 16                      | 2              | Urinary, temporal    | Bleeding tendency     |
| 8       | 84  | M   | SFTS                      | 38                      | 2              | Soft tissue, persistent | Bleeding tendency     |
| 9       | 28  | M   | AML                       | 13                      | 3              | Trachea, persistent  | Bleeding tendency     |
| 10      | 73  | M   | Liver abscess             | 38                      | 0              | None                | Before the invasive procedure |

F female; M male; SLE systemic lupus erythematosus; TAFRO thrombocytopenia, anasarca, myelofibrosis, renal dysfunction, and organomegaly; SFTS severe fever with thrombocytopenia syndrome; AML acute myeloid leukemia; GI gastrointestinal

Table 2  Patients’ hemostatic values before platelet transfusion

| Hemostatic parameter | Major bleeding group (mean ± SD) | Minor bleeding group (mean ± SD) | P     |
|----------------------|---------------------------------|---------------------------------|-------|
| General tests        |                                 |                                 |       |
| Platelet (10³/µL)    | 27.2 ± 18.2                     | 39.8 ± 11.6                     | 0.259 |
| PT-INR               | 1.4 ± 0.5                       | 1.5 ± 0.5                       | 0.733 |
| PT (sec)             | 16.3 ± 5.3                      | 17.8 ± 5.7                      | 0.676 |
| APTT (sec)           | 71.2 ± 28.7                     | 74.8 ± 41.0                     | 0.872 |
| Fibrinogen (mg/dl)   | 414.5 ± 343.0                   | 385.8 ± 439.9                   | 0.910 |
| ROTEM                |                                 |                                 |       |
| EXTEM clotting time (sec) | 94.5 ± 18.7                     | 64.5 ± 13.4                     | 0.025 |
| EXTEM MCF (mm)       | 41.0 ± 5.7                      | 44.3 ± 12.4                     | 0.583 |
| INTEM clotting time (sec) | 299.2 ± 85.9                    | 284.3 ± 55.3                    | 0.768 |
| INTEM MCF (mm)       | 39.5 ± 4.4                      | 40.8 ± 12.6                     | 0.824 |
| Multiplate           |                                 |                                 |       |
| Collagen-induced aggregation (U) | 67.5 ± 51.6                     | 100.5 ± 23.0                    | 0.270 |
| ADP-induced aggregation (U) | 19.3 ± 17.2                     | 42.0 ± 17.7                     | 0.078 |
| TRAP-induced aggregation (U) | 44.3 ± 46.2                     | 69.8 ± 23.2                     | 0.344 |
| Ristocetin-induced aggregation (U) | 8.7 ± 8.4                       | 5.0 ± 3.4                       | 0.439 |
| T-TAS                |                                 |                                 |       |
| Occlusion time (min) | > 30                            | 163.3 ± 3.3                     | < 0.01 |
| AUC                  | 1715 ± 305.3                    | 1291.2 ± 298.7                  | < 0.01 |

SD standard deviation; PT prothrombin time; INR international normalized ratio; APTT activated partial thromboplastin time; MCF maximum clot firmness; ADP adenosine diphosphate; TRAP thrombin receptor activating peptide; AUC area under the curve
clinical question requires prospective investigation of how the frequency of bleeding events and platelet transfusion differ when criteria based on the T-TAS versus platelet counts are applied. Such interventional studies may not be approved at this time because insufficient data are available to ensure that the T-TAS may be safely used to make clinical decisions. We therefore consider that the present study is a first step in this direction.

Efficient hemostasis requires sufficient numbers of functional platelets as well as coagulation factors [26, 27]. If platelet function is compromised, hemostasis is impaired regardless of platelet count. For example, the platelet counts in patients #8 and #10 were similar, although the thrombogenicity of the former was low according to T-TAS data, and bleeding symptoms were apparent. The risk of bleeding might be more accurately evaluated with a comprehensive analysis of hemostatic function using the T-TAS. This might be an advantage of the T-TAS in comparison with specific tests targeting platelets or coagulation function.

The recovery of thrombogenic potential after platelet transfusion was confirmed in most patients, with the exception of patient #9. Table 3 indicates that patients with a low AUC of the T-TAS after platelet transfusion required additional platelet transfusion within the next few days. Thus, the platelet transfusion in patient #9 on day 1 might have had limited effectiveness. This finding might have resulted partly from the relatively low function of the transfused platelets and the fact that the background disease did not allow recovery of platelet count in this patient.

The 10 patients tested in the present study had different underlying diseases. It is important to consider
whether the cut-off values must be changed according to the underlying disease when making clinical decisions. Although it is possible that thrombogenic potential can be uniformly determined with the T-TAS regardless of underlying disease, the T-TAS is unable to evaluate the vulnerability of blood vessels, which is one factor that contributes to bleeding [28–31]. Thus, the T-TAS may underestimate the risk of bleeding in diseases associated with vascular abnormalities. Detailed analysis of each underlying disease will be required in the future.

| Patient | Bleeding Scale | AUC of T-TAS Before | AUC of T-TAS After | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 |
|---------|----------------|---------------------|-------------------|------|------|------|------|------|------|------|
| 1       | 1              | 984.5               | 1188.1            | ●    |      |      |      |      |      |      |
| 2       | 3              | 128.3               | 929.9             | ●    |      |      |      |      |      |      |
| 3       | 0              | 1150.1              | 1572.4            | ●    |      |      |      |      |      |      |
| 4       | 2              | 27.5                | 907.4             | ●    |      |      |      |      |      |      |
| 5       | 4              | 20.4                | 1164.9            | ●    | ●    |      |      |      |      |      |
| 6       | 1              | 1351.4              | 1607.3            | ●    |      |      |      |      |      |      |
| 7       | 2              | 38.3                | 568.2             | ●    | ●    |      |      |      |      |      |
| 8       | 2              | 789.2               | 1694.2            | ●    |      |      |      |      |      |      |
| 9       | 3              | 25.3                | 34.3              | ●    | ●    | ●    | ●    | ●    | ●    | ●    |
| 10      | 0              | 1678.6              | 1734              | ●    |      |      |      |      |      |      |

● indicates the day requiring platelet transfusion. The requirement for platelet transfusion was determined in accordance with our standard clinical practice, independent of the present study.

Fig. 4 Hemostatic function recovery rate depends on platelet function, not count, in transfused platelet concentrate. (Upper left) Correlation between the difference in the AUC of the T-TAS of blood collected before versus after platelet transfusion (ΔAUC of T-TAS in patients) and the AUC of the T-TAS of platelet concentrate (PLTc); Pearson’s correlation coefficient (r) = 0.748, P = 0.021. (Upper middle) Correlation between the ΔAUC of the T-TAS in patients and the AUC of the Multiplate Analyzer; r = 0.535, P = 0.138. (Upper right) Correlation between the ΔAUC of the T-TAS in patients and the platelet number of the PLTc; r = 0.129, P = 0.740. (Lower left) Correlation between the AUC of the T-TAS of PLTc and the platelet number of the PLTc; r = 0.298, P = 0.436. (Lower middle) Relationship between the AUC of the T-TAS and the storage period of PLTc (days between blood donation and transfusion). (Lower right) Relationship between the ΔAUC of the T-TAS in patients and the storage period of PLTc. The data for one of the 10 PLTc were unavailable, and thus nine cases were analyzed.
Conclusions

We developed a modified microchip (HD chip)-based flow chamber system suitable for evaluating the thrombogenicity of patients with thrombocytopenia. For analysis of blood samples with normal platelet counts, we still recommend using conventional AR chips.

Abbreviations

ADP: Adenosine diphosphate; APTT: Activated partial thromboplastin time; AUC: Area under the curve; ICU: Intensive care unit; PT: Prothrombin time; ROTEM: Rotational thromboelastometry; TRAP-6: Thrombin receptor activating peptide-6; T-TAS: Total thrombus-formation analysis system

Acknowledgments

The authors thank DMC Corp. for editing drafts of this manuscript. We also thank Rebecca Tollefson, DVM, from Edanz Group (https://en-author-services.edanzgroup.com/ac) for editing a draft of this manuscript.

Authors’ contributions

BA recruited patients, analyzed data, and wrote the manuscript. TI designed the experimental protocol and wrote the manuscript. TN, TO, and KH participated in the preparation of new microchips for T-TAS analysis. TY, IM, and YK critically appraised the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by research grants from the Japan Society for the Promotion of Science (Grants-in-Aid 19 K18330) and Fujimori Kogyo Co., Ltd.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

The Ethics Committee of Kagoshima University Hospital approved this single-center observational study. Written informed consent to participate in this study was obtained from all patients or their close relatives.

Consent for publication

Not applicable.

Competing interests

TN, TO, and KH are employed by Fujimori Kogyo Co., Ltd, where the T-TAS HD chips were developed. TI and IM hold endowed faculty positions at Kagoshima University and receive research funding from Fujimori Kogyo Co., Ltd. The other authors have no conflicts of interest.

Author details

1Department of Emergency and Intensive Care Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. 2Department of Systems Biology in Thromboregulation, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan. 3Research Institute, Fujimori Kogyo Co., Ltd., Yokohama, Japan.

Received: 16 August 2020 Accepted: 22 October 2020

Published online: 30 October 2020

References

1. Smock KJ, Perkins SL. Thrombocytopenia: an update. Int J Lab Hematol. 2014;36(3):269–78.
2. Rankin JS, Stratton CW. Efficacy of immunomodulation in the treatment of profound thrombocytopenia after adult cardiac surgery. J Thorac Cardiovasc Surg. 2014;147(2):808–13. discussion 813-805.
3. Sinkoš, A, Majal M. The impact of thrombocytopenia on outcome in patients with acute coronary syndromes: a single center retrospective study. Biomed Res Int. 2015;2015:907304.
4. Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinnmouth AT, Capocelli KE, Cipolle MD, Cohn CS, Fung MK, Grossman BJ, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med. 2015;162(3):205–13.
5. Estcourt LJ, Birchall J, Lowe D, Grant-Casey J, Rowley M, Murphy MF. Platelet transfusions in haematology patients: are we using them appropriately? Vox Sang. 2012;103(4):284–93.
6. Liambroto G, Bennardello F, Lattano A, Piccoli P, Rossetti G. Recommendations for the transfusion of plasma and platelets. Blood Transfus. 2009;7(2):132–50.
7. Slieker SJ. Evidence-based platelet transfusion guidelines. Hematol Am Soc Hematol Educ Program. 2007;2007(1):172–8. https://doi.org/10.1182/asheducation-2007.1.172.
8. Schiffer CA, Anderson RC, Bennett CL, Bernstein S, Elting LS, Goldsmith M, Goldstein M, Hume H, McCullough J, Mclntyre RE, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19(5):1519–38.
9. Murphy S, Utvin S, Herring LM, Koch P, Remishovski J, Donaldson MH, Evans AE, Gardner FH. Indications for platelet transfusion in children with acute leukemia. Am J Hematol. 1982;12(4):347–56.
10. Wans J, Schaefer-Eckart K, Wendelin K, Pitz B, Wilhelm M, Thalleimer M, Mahlkec L, Ho A, Sachtel, A, Kramer M, et al. Therapeutic platelet transfusion versus routine prophylactic platelet transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet. 2012;380(9860):1309–16.
11. Stanworth SJ, Estcourt LJ, Powter G, Kahan BC, Dyer C, Choo L, Bakrania L, Liewelyn C, Littlewood T, Soular R, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013;368(19):1771–80.
12. Rebull PA, Finazzi G, Marangon F, Avisati G, Gugliotta I, Tognoni G, Barbui T, Mandelli F, Siccia G. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. N Engl J Med. 1997;337(26):1870–5.
13. Heckman RD, Weiner GJ, Davis CS, Strauss RG, Jones MP, Burns CP. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL. J Clin Oncol. 1997;15(3):1143–9.
14. Zumberg MS, del Rosario ML, Nejame CE, Pollock RH, Garzarrella L, Kao KJ, Lottenberg R, Wingard JR. A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/microL versus 20,000/microL. Transfusion. 2009;7(2):132.
15. Friedmann AM, Sengul H, Lehmann H, Schwartz C, Goodman S. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev. 2002;16(1):34–45.
16. 13. Friedmann AM, Sengul H, Lehmann H, Schwartz C, Goodman S. Do basic laboratory tests or clinical observations predict bleeding in thrombocytopenic oncology patients? A reevaluation of prophylactic platelet transfusions. Transfus Med Rev. 2002;16(1):34–45.
17. 17. Toth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode Aggregometry in cardiac surgery and major trauma. J Cardiothorac Vasc Anesth. 2012;26(6):1083–8.
18. 18. Kirmani BH, Johnson RI, Agarwal S. Platelet function testing in cardiac surgery patients. Acta Anaesthesiol Scand. 2019;63(4):475–8.
19. 19. Toth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electrode Aggregometry in cardiac surgery and major trauma. J Cardiothorac Vasc Anesth. 2012;26(6):1083–8.
20. 20. Kirmani BH, Johnson RI, Agarwal S. Platelet function testing in cardiac surgery patients. Acta Anaesthesiol Scand. 2019;63(4):475–8.
21. 21. Shams Hakimi C, Singh S, Hesse C, Jeppsson A. Effects of fibrinogen and thrombomodulin on thrombus formation and antithrombotic agents under blood flow conditions. J Biolog Blood Marrow Transplant. 2002;8(10):569–76.
22. 22. Shams Hakimi C, Singh S, Hesse C, Jeppsson A. Effects of fibrinogen and thrombomodulin on thrombus formation and antithrombotic agents under blood flow conditions. J Biolog Blood Marrow Transplant. 2002;8(10):569–76.
Thrombus formation in cardiovascular disease. Thromb Haemost. 2019; 19(10):1554–62.

24. Mitsuse T, Kaikita K, Ishii M, Oimatsu Y, Nakanishi N, Ito M, Arima Y, Sueta D, Iwashita S, Fujisue K, et al. Total Thrombus-formation analysis system can predict 1-year bleeding events in patients with coronary artery disease. J Atheroscler Thromb. 2020;27(3):215–26.

25. Yamamoto K, Ito T, Nagasato T, Shinnakasu A, Kurano M, Arimura A, Arimura H, Hashiguchi H, Deguchi T, Maruyama I, et al. Effects of glycemic control and hypoglycemia on Thrombus formation assessed using automated microchip flow chamber system: an exploratory observational study. Thromb J. 2019;17:17.

26. Daugirdas JT, Bernardo AA. Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia. Kidney Int. 2012; 82(2):147–57.

27. Paniccia R, Priola R, Liotta AA, Abbate R. Platelet function tests: a comparative review. Vasc Health Risk Manag. 2015;11:133–48.

28. Corada M, Mariotti M, Thurston G, Smith K, Kunkel R, Brockhaus M, Lampugnani MG, Martin-Padura I, Stoppacciaro A, Ruco L, et al. Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci U S A. 1999;96(17):9815–20.

29. Dejana E, Tournier-Lasserve E, Weinstein BM. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev Cell. 2009;16(2):209–21.

30. Malfait F. Vascular aspects of the Ehlers-Danlos syndromes. Matrix Biol. 2018; 71-72:380–95.

31. Wylie LA, Mouillesseaux KP, Chong DC, Bautch VL. Developmental SMAD6 loss leads to blood vessel hemorrhage and disrupted endothelial cell junctions. Dev Biol. 2018;442(2):199–209.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.